Trials / Completed
CompletedNCT00238719
Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 293 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 8 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venlafaxine ER |
Timeline
- Start date
- 1999-12-01
- Completion
- 2003-06-01
- First posted
- 2005-10-13
- Last updated
- 2006-05-19
Source: ClinicalTrials.gov record NCT00238719. Inclusion in this directory is not an endorsement.